Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Antibacterial Drugs Market $50 Billion by 2029

The global market for antibacterial drugs market projected to reach $50 billion by 2029, growing slowly at a CAGR of 1.6% over the forecast period, driven by increasing incidence of infectious diseases, and emerging multi-drug resistant bacterial strains in various parts of the world.

  • Antibacterial resistance is a great concern and requires global action. Bacterial resistance is a growing problem worldwide and is estimated that deaths by infectious diseases associated with resistant pathogens will generate 10 million deaths per year in 2050.
  • However, the scientific difficulties, an unfavorable regulatory climate, multiple company mergers and the low financial returns associated with antibiotic drug development have led to the withdrawal of many pharmaceutical companies from the field.
Global Antibacterial Drugs Market

Antibacterials are commonly classified based on their mechanism of action or spectrum of activity.

  • The main classes of antibacterial drugs target only four classical bacterial functions: bacterial-cell-wall biosynthesis (e.g., penicillin and vancomycin); bacterial protein biosynthesis (e.g., aminoglycoside and macrolide); DNA and RNA replication (e.g., ciprofloxacin and rifampin); and folate coenzyme biosynthesis (e.g., sulfamethoxazole).
    • A recent WHO report on “Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including Mycobacterium tuberculosis” – shows a serious lack of new antibiotics under development to combat the growing threat of antimicrobial resistance.
      • Most of the drugs currently in the clinical pipeline are modifications of existing classes of antibiotics and are only short-term solutions.

Novel classes of antibacterial drugs in clinical development include:

  • The regulatory climate has now begun to improve, but major scientific hurdles still impede the discovery and development of novel antibacterial agents.
  • In the last decade of a total of 293 new drugs approved by the FDA, only 9 corresponded to antimicrobial drugs and none constituted a new structural class.
    • The majority of the molecules in the clinical phase II or III, coming from modifications of drugs in clinical use, this strategy makes easier the bacterial susceptibility to generate resistance through the mechanisms expressed for their drug predecessors.
      • The preclinical antibacterial pipeline reveals innovative strategies when contrasted with the current global antibacterial clinical pipeline, which mainly builds on modification of known antibiotic classes.
        • However, the pipelines are highly fragile in SMEs for many reasons. Major basic scientific challenges such as penetration, efflux and the associated risk of toxicity owing to required high doses need an expanded concerted research agenda to advance discovery efforts for traditional antibiotics. 
    • By understanding the causes of the failures and successes of the pharmaceutical industry’s research history, duplication of discovery programmes can be reduced, increasing the productivity of the antibiotic drug discovery pipeline by academia and small companies. 
Novel classes of antibacterial crugs in clinical development

The global antibacterial drugs market report estimates the market size ($million 2019 to 2029), market share, growth trends and forecast (CAGR% 2023 to 2029).

The global market for antibacterial drugs segmented by drug class [aminoglycosides, β-lactams (penicillins, carbapenems, cephalosporin), macrolides, phenicols, quinolones/fluoroquinolone, sulfonamides, tetracyclines. others], route of administration (enteral, parenteral, others), distribution channel (hospital pharmacies, drug stores, retail pharmacies, online sales), by pipeline analysis, and geography. 

  • Based on the drug classes, the β-lactams segment accounted for the largest share of the total antibacterials market, whereas the phenicols drug class segment anticipated to witness thr fastest growth rate over the coming years.
    • The global antibacterials market is highly saturated and has significant generic penetration, yet still experiences continuous growth due to increasing sales volume, as well as the rise of premium-priced novel treatments for resistant bacteria.
  • Key drivers for this market include the growing number of people with weakened immune systems, such as the elderly and immunosuppressed patients (HIV patients and organ recipients).
    • However, the development of antibacterial drugs has become increasingly unattractive to big pharma for a number of reasons:
      • short antibacterial drug life-cycle due to bacterial resistance; 
      • the fact that antibacterial therapy is acute, not chronic;
      • the mature nature of the market, which is characterized by low growth and high generic penetration;
      • the raising of the bar for the statistical standards needed to show the efficacy of experimental drugs in clinical trials.
  • For many antibiotics, the oral administration results in therapeutic blood levels nearly as rapidly as IV administration.
    • However, the IV administration is preferred in the under certain circumstances. 
    • Various efforts have been made to develop the newer antimicrobial with novel modes of action which can act against these multi-drug resistant strains.
      • With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market.
  • Although there are good treatment options available for most common infections, several opportunities exist in niche indications with high unmet needs.
    • The most significant are oral drugs to treat MRSA, the prevalence of which has dramatically increased in both hospital and community settings since past decade. 
  • Two trends that are shaping the antibacterial market include patent expiries and the smaller hospital market continues to expand rapidly, driven by rising resistance rates, a more severely ill patient population and newer, premium-priced injectable antibiotics.

The global antibacterials market research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World.

The global antibacterial drugs market report also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.

Major players operating in the global antibacterial drugsmarket and included in this report are AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly & Co., Allergan plc (AbbVie, Inc.), GlaxoSmithKline plc, Novartis AG, Pfizer, Inc., Merck & Co., Inc., and others.

  • Drug Class
    • Aminoglycosides
    • β-Lactams
      • Penicillin
      • Carbapenem
      • Cephalosporin
    • Macrolides
    • Phenicols
    • Quinolones/Fluoroquinolones
    • Sulfonamides
    • Tetracyclines
    • Other Antibacterials
  • Route of Administration
    • Enteral
    • Parenteral
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Drug Stores and Retail Pharmacies
    • Online Sales
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Allergan plc (AbbVie, Inc.)
    • AstraZeneca plc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi S.A.

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com